Melanie Janning

List of Publications by Year
in descending order

31 papers	758 citations	687363 13 h-index	526287 27 g-index
31 all docs	31 docs citations	31 times ranked	1670 citing authors

#	Article	IF	Citations
1	Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. Lung Cancer, 2022, 164, 46-51.	2.0	3
2	Abstract 3374: Large-scale single-cell whole transcriptomic analyses reveal distinct malignant phenotypes of CTCs from NSCLC patients. Cancer Research, 2022, 82, 3374-3374.	0.9	1
3	CD74 and CD44 Expression on CTCs in Cancer Patients with Brain Metastasis. International Journal of Molecular Sciences, 2021, 22, 6993.	4.1	26
4	Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. Cells, 2020, 9, 2337.	4.1	13
5	Multicenter Evaluation of Independent High-Throughput and RT-qPCR Technologies for the Development of Analytical Workflows for Circulating miRNA Analysis. Cancers, 2020, 12, 1166.	3.7	10
6	Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC). OncoImmunology, 2020, 9, 1738798.	4.6	34
7	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology, 2020, 190, e169-e173.	2.5	14
8	Influence of Androgens on Immunity to Self and Foreign: Effects on Immunity and Cancer. Frontiers in Immunology, 2020, 11, 1184.	4.8	65
9	Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer Patients. Cancers, 2020, 12, 442.	3.7	28
10	Integrative public data-mining pipeline for theÂvalidation of novel independent prognostic biomarkers for lung adenocarcinoma. Biomarkers in Medicine, 2020, 14, 1651-1662.	1.4	0
11	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868.	5.1	12
12	Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Cancers, 2019, 11, 835.	3.7	109
13	Abstract 2219: Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma of the bladder. , 2019, , .		1
14	Anti-Angiogenics: Their Value in Lung Cancer Therapy. Oncology Research and Treatment, 2018, 41, 172-180.	1.2	34
15	Phase I/<scp>II</scp> study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (<scp>AMLSG</scp> 17â€10 <scp>CIARA</scp> trial). British Journal of Haematology, 2018, 183, 235-241.	2.5	2
16	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	1.1	18
17	Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS. Blood, 2018, 132, 2672-2672.	1.4	5
18	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. Journal of Clinical Oncology, 2018, 36, 7020-7020.	1.6	1

#	Article	IF	Citations
19	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. Journal of Clinical Oncology, 2018, 36, 70-70.	1.6	1
20	Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients. , 2018, , .		0
21	Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. Journal of Clinical Oncology, 2017, 35, 11522-11522.	1.6	1
22	BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles. Blood, 2016, 128, 592-592.	1.4	1
23	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) Tj ETQq1 1 0.784314 rgBT /Overlo	1.4	3
24	Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget, 2015, 6, 6341-6358.	1.8	28
25	Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?. Expert Review of Hematology, 2015, 8, 135-138.	2.2	21
26	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. British Journal of Haematology, 2015, 169, 694-700.	2.5	90
27	Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3). Journal of Biological Chemistry, 2015, 290, 25275-25292.	3.4	33
28	Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncology, 2014, 10, 1157-1165.	2.4	22
29	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. Blood, 2014, 124, 4512-4512.	1.4	1
30	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013, 122, 2443-2452.	1.4	178
31	Acute Megakaryoblastic Leukemia in a Patient with Xeroderma Pigmentosum: Discussion of Pathophysiological, Prognostic, and Toxicological Aspects. Acta Haematologica, 2013, 129, 121-125.	1.4	6